Analysis of the EAP, page-805

@Yor, yes, interesting, I don't follow CAPR very closely but if I were a shareholder over there I'd be a bit upset... It's a sleepy microcap in March with a market cap of about US$10M studying DMD as you point out. They announce good results with their C-19 EAP and the stock is up 12-fold at one point - though we should note at least one patient was not on a ventilator suggesting they enrolled easier-to-treat patients than MSB, ie perhaps some who might have recovered anyhow. They use the surge in stock price to raise capital at an average $7.34... then announce, "never mind" we're not going to pursue a therapeutic, rather a vaccine. It does make it look like they used the EAP and those patients for the primary purpose of a CR... I've always had questions about their IP too, even though they're using cadaveric cardiac cells.

Yes, it would be interesting to see if one of the vaccine manufactures might license rem-L as a "small protein-antigen delivery device" for enhanced antigenicity of whatever antigen they happen to be working on. "Effective and fast", maybe not so far-fetched... perhaps "cell-mediated" immunity in both senses of the term.